Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for Degenerated Disc Disease
NCT03692221Phase 1Withdrawn
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous bone marrow derived mesenchymal stromal cells in intervertebral disc degeneration (DDD) (3 arms), sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Rate of treatment related adverse events at 1 year. Planned start Jun 2019; status: withdrawn.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
intervertebral disc degeneration (DDD)
Beyond the preview
Go deeper on NCT03692221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692221.